Report cover image

MEA Biologics and Biosimilar Market

Publisher Future Market Insights
Published Feb 21, 2023
Length 298 Pages
SKU # FMARI19095785

Description

MEA Biologics and Biosimilar Market


MEA Biologics and Biosimilar Market: Global Industry Analysis 2017-2022 and Opportunity Assessment 2023-2033

A recent market study published by FMI on MEA Biologics and Biosimilar offers a global industry analysis for 2017-2022 and opportunity assessment for 2023-2033. The study offers a comprehensive assessment of the most important market dynamics. After conducting thorough research on the historical and current growth parameters, the growth prospects of the market are obtained with maximum precision.

Market Segmentation

By Drug:
  • Adalimumab
  • Bevacizumab
  • Trastuzumab
  • Ustekinumab
  • Golimumab
  • Eculizumab
  • Rituximab
By Drug Class:
  • Antirheumatics
  • TNF Alfa Inhibitors
  • VEGF/VEGFR Inhibitors
  • HER2 Inhibitors
  • Selective Immunosuppressant’s
  • Interleukin Inhibitors
By Dosage Form:
  • Subcutaneous
  • Intravenous
By Indication:
  • Cancer
  • Arthritis
  • Rheumatoid

  • Psoriatic

  • Others
  • Skin Disorders
  • Plaque-Type Psoriasis

  • Hidradenitis Suppurativa
  • Inflammatory Bowel Disease (IBD)
  • Crohn's Disease

  • Ulcerative Colitis
  • Rare Disease
  • Others
    • By Distribution Channel:
    • Hospitals
  • Specialty Clinics

  • Cancer Research Centers
  • Retail Sales
  • Retail Pharmacies

  • Mail Order Pharmacies /Online Sales

    • By Country:
    • UAE
    • Bahrain
    • Iraq
    • Jordan
    • Kuwait
    • Lebanon
    • Oman
    • Qatar
    • KSA
    • Iran
    • Palestine
    Report Chapters

    Executive Summary

    The executive summary of the MEA Biologics and Biosimilar Market includes the global market outlook, demand side trends, supply side trends and also include FMI analysis and recommendations of Vehicle Radar Test System.

    Chapter 01 - Market Overview

    Readers can find the detailed segmentation and definition of the MEA Biologics and Biosimilar Market in this chapter, which will help to understand basic information about Vehicle Radar Test System. This section also highlights the market scope, taxonomy and limitations which help the reader understand the market coverage of MEA Biologics and Biosimilar Market report.

    Chapter 02 - Market Background

    This chapter includes detailed analysis of the By Drug processing methods overview, consumer buying patterns & tendencies and policy developments and regulatory scenario. It also includes in depth analysis of macro-economic factors and covers topics like global GDP growth outlook, global industry value added, personal consumption, expenditures, modern trade penetration and consumer price indices. The chapter also covers forecast factors - relevance & impact, value chain analysis and market dynamics (drivers, restraints and opportunities) to better understand the market.

    Chapter 03 - Global MEA Biologics and Biosimilar Market Demand Analysis 2017-2022 and Forecast, 2023-2033

    The chapter include historical market value (US$ 485.9 Million) analysis (2017-2022) and current and future market value (US$ 512.6 Million) and volume (5.5%) projections (2023-2033). The projections are based on the Y-O-Y growth trend analysis and absolute $ opportunity analysis country of operation.

    Chapter 04 - Global MEA Biologics and Biosimilar Market - Pricing Analysis

    Based on By Drug, the pricing analysis chapter include Regional pricing analysis (USD/MT), global average pricing analysis benchmark, and key factors impacting the pricing.

    Chapter 05 - Global MEA Biologics and Biosimilar Market Analysis 2017-2022 and Forecast 2023-2033, By Drug

    Based on By Drug, MEA Biologics and Biosimilar Market is segmented into Adalimumab, Bevacizumab, Trastuzumab, Ustekinumab, Golimumab, Eculizumab, Rituximab. Value forecast and Y-o-Y growth comparison will also be provided for above mentioned By Drug.

    Chapter 06 - Global MEA Biologics and Biosimilar Market Analysis 2017-2022 and Forecast 2023-2033, By Drug Class

    Based on By Drug Class, MEA Biologics and Biosimilar Market is segmented into Antirheumatics, TNF Alfa Inhibitors, VEGF/VEGFR Inhibitors, HER2 Inhibitors, Selective Immunosuppressant’s, Interleukin Inhibitors. This section also offers market attractiveness analysis based on By Drug Class. Value forecast and Y-o-Y growth comparison will also be provided for above mentioned By Drug Class.

    Chapter 07 - Global MEA Biologics and Biosimilar Market Analysis 2017-2022 and Forecast 2023-2033, By Dosage Form

    Based on By Dosage Form, MEA Biologics and Biosimilar Market is segmented into Subcutaneous, Intravenous. This section also offers market attractiveness analysis based on By Dosage Form. Value forecast and Y-o-Y growth comparison will also be provided for above mentioned By Dosage Form.

    Chapter 08 - Global MEA Biologics and Biosimilar Market Analysis 2017-2022 and Forecast 2023-2033, By Indication

    Based on By Indication, MEA Biologics and Biosimilar Market is segmented into Cancer, Arthritis (Rheumatoid, Psoriatic, Others), Skin Disorders (Plaque-Type Psoriasis, Hidradenitis Suppurativa), Inflammatory Bowel Disease (IBD)(Crohn's Disease, Ulcerative Colitis), Rare Disease, Others. This section also offers market attractiveness analysis based on By Indication. Value forecast and Y-o-Y growth comparison will also be provided for above mentioned By Indication.

    Chapter 09 - Global MEA Biologics and Biosimilar Market Analysis 2017-2022 and Forecast 2023-2033, By Distribution Channel

    Based on By Distribution Channel, MEA Biologics and Biosimilar Market is segmented into Hospitals (Specialty Clinics, Cancer Research Centers), Retail Sales (Retail Pharmacies, Mail Order Pharmacies /Online Sales). This section also offers market attractiveness analysis based on By Distribution Channel. Value forecast and Y-o-Y growth comparison will also be provided for above mentioned By Distribution Channel.

    Chapter 10 - MEA Biologics and Biosimilar Market Analysis 2017-2022 and Forecast 2023-2033, By Country

    Based on By Country, MEA Biologics and Biosimilar Market is segmented into UAE, Bahrain, Iraq, Jordan, Kuwait, Lebanon, Oman, Qatar, KSA, Iran, Palestine. This section also offers market attractiveness analysis based on By Country. Readers can also find value forecast and Y-o-Y growth comparison for all above mentioned By Country.

    Chapter 11 - Key Countries MEA Biologics and Biosimilar Market Analysis 2017-2022 and Forecast 2023-2033

    This chapter offers insights into how the MEA Biologics and Biosimilar Market is expected to grow in major countries globally.

    Chapter 12 - Market Structure Analysis- Global Assessment

    This chapter includes company dashboard, industry structure analysis by tier of companies, 2022E, company share analysis of top players, 2022E, and competition benchmarking- matrix.

    Chapter 13 - Competition Deep Dive (Tentative List)

    This chapter includes company overview, By Drug portfolio of companies, profitability by market segments, sales footprint, SWOT analysis and strategy overview of the companies being studied in the report. Some of the market players featured in the report are AbbVie Inc., Eisai Co Ltd, Zydus Cadila(Cadila Healthcare), Amneal Pharmaceuticals, Inc., Pfizer Inc., Celltrion, Inc., Coherus BioSciences, Inc., F. Hoffmann–La Roche Ltd (Genentech, Inc.), Alexion(Astrazeneca), Johnson & Johnson, Amgen, Hikma pharmaceuticals plc..

    Chapter 14 - Assumptions and Acronyms

    This chapter includes a list of acronyms and assumptions that provide a base to the information and statistics included in the Vehicle Radar Test System report.

    Chapter 15 - Research Methodology

    This chapter helps readers understand the research methodology followed to obtain various conclusions, as well as important qualitative and quantitative information, on MEA Biologics and Biosimilar Market.

    Table of Contents

    298 Pages
    1. Executive Summary | MEA Biologics and Biosimilar Market
    1.1. MEA Market Outlook
    1.2. Demand Side Trends
    1.3. Supply Side Trends
    1.4. Analysis and Recommendations
    2. Market Overview
    2.1. Market Coverage / Taxonomy
    2.2. Market Definition / Scope / Limitations
    2.3. Inclusions & Exclusions
    3. Key Market Trends
    3.1. Key Trends Impacting the Market
    3.2. Drug Innovation / Development Trends
    4. Key Success Factors
    4.1. Regulatory Scenario
    4.2. Pipeline Assessment
    4.3. Key Marketing & Promotional Strategies Adopted by Companies
    4.4. PESTLE Analysis
    4.5. Porter’s Analysis
    4.6. Value Chain Analysis
    5. Market Background
    5.1. Macro–Economic Factors
     5.1.1. MEA GDP Growth Outlook
     5.1.2. MEA Healthcare Expenditure
     5.1.3. Global Market Overview
    5.2. Forecast Factors - Relevance & Impact
     5.2.1. Increase in Research and Development Funding and Grants
     5.2.2. High Demand for Biologics
     5.2.3. Surge in Research Collaborations for the Development of Drugs
     5.2.4. New Product Launch
     5.2.5. Regulatory Approvals
     5.2.6. Cost of Drugs
    5.3. Market Dynamics
     5.3.1. Drivers
     5.3.2. Restraints
     5.3.3. Opportunity Analysis
    6. COVID-19 Crisis Analysis
    6.1. COVID-19 and Impact Analysis
     6.1.1. Revenue By Drug
     6.1.2. Revenue By Drug Class
     6.1.3. Revenue By Dosage Form
     6.1.4. Revenue By Indication
     6.1.5. Revenue By Distribution Channel
     6.1.6. Revenue By Country
    6.2. 2021 Market Scenario
    7. MEA Market Demand Volume (Units) Analysis 2017 to 2022 and Forecast 2023 to 2033
    7.1. Historical Market Volume (Units) Analysis, 2017 to 2022
    7.2. Current and Future Market Volume (Units) Projections, 2023 to 2033
     7.2.1. Y–o–Y Growth Trend Analysis
    8. MEA Market - Pricing Analysis
    8.1. MEA Average Pricing Analysis Benchmark
    8.2. Pricing Assumptions
    9. MEA Market Demand (in Value or Size in US$ Million) Analysis 2017 to 2022 and Forecast 2023 to 2033
    9.1. Historical Market Value (US$ Million) Analysis, 2017 to 2022
    9.2. Current Market Value (US$ Million) Forecast 2023 to 2033
     9.2.1. Y–o–Y Growth Trend Analysis
     9.2.2. Absolute $ Opportunity Analysis
    10. MEA Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Drug
    10.1. Introduction / Key Findings
    10.2. Historical Market Size (US$ Million) and Volume (Units) Analysis By Drug, 2017 to 2022
    10.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis By Drug, 2023 to 2033
     10.3.1. Adalimumab
     10.3.2. Bevacizumab
     10.3.3. Trastuzumab
     10.3.4. Ustekinumab
     10.3.5. Golimumab
     10.3.6. Eculizumab
     10.3.7. Rituximab
    10.4. Market Attractiveness Analysis By Drug
    11. MEA Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Drug Class
    11.1. Introduction / Key Findings
    11.2. Historical Market Size (US$ Million) Analysis By Drug Class, 2017 to 2022
    11.3. Current and Future Market Size (US$ Million) Analysis By Drug Class, 2023 to 2033
     11.3.1. Antirheumatics
     11.3.2. TNF Alfa Inhibitors
     11.3.3. VEGF/VEGFR Inhibitors
     11.3.4. HER2 Inhibitors
     11.3.5. Selective Immunosuppressants
     11.3.6. Interleukin Inhibitors
    11.4. Market Attractiveness Analysis By Drug Class
    12. MEA Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Dosage Form
    12.1. Introduction / Key Findings
    12.2. Historical Market Size (US$ Million) Analysis By Dosage Form, 2017 to 2022
    12.3. Current and Future Market Size (US$ Million) Analysis By Dosage Form, 2023 to 2033
     12.3.1. Subcutaneous
     12.3.2. Intravenous
    12.4. Market Attractiveness Analysis By Dosage Form
    13. MEA Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Indication
    13.1. Introduction / Key Findings
    13.2. Historical Market Size (US$ Million) Analysis By Indication, 2017 to 2022
    13.3. Current and Future Market Size (US$ Million) Analysis By Indication, 2023 to 2033
     13.3.1. Cancer
     13.3.2. Arthritis
     13.3.2.1. Rheumatoid
     13.3.2.2. Psoriatic
     13.3.2.3. Others
     13.3.3. Skin Disorders
     13.3.3.1. Plaque-Type Psoriasis
     13.3.3.2. Hidradenitis Suppurativa
     13.3.4. Inflammatory Bowel Disease (IBD)
     13.3.4.1. Crohn's Disease
     13.3.4.2. Ulcerative Colitis
     13.3.5. Rare Disease
     13.3.6. Others
    13.4. Market Attractiveness Analysis By Indication
    14. MEA Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Distribution Channel
    14.1. Introduction / Key Findings
    14.2. Historical Market Size (US$ Million) Analysis By Distribution Channel, 2017 to 2022
    14.3. Current and Future Market Size (US$ Million) Analysis By Distribution Channel, 2023 to 2033
     14.3.1. Institutional Sales
     14.3.1.1. Hospitals
     14.3.1.2. Specialty Clinics
     14.3.1.3. Cancer Research Centers
     14.3.2. Retail Sales
     14.3.2.1. Retail Pharmacies
     14.3.2.2. Mail Order Pharmacies/Online Sales
    14.4. Market Attractiveness Analysis By Distribution Channel
    15. MEA Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Country
    15.1. Introduction
    15.2. Historical Market Size (US$ Million) Analysis, By Country, 2017 to 2022
    15.3. Current and Future Market Size (US$ Million) Analysis By Country, 2023 to 2033
     15.3.1. UAE
     15.3.2. Kuwait
     15.3.3. Qatar
     15.3.4. Bahrain
     15.3.5. Oman
     15.3.6. Lebanon
     15.3.7. Jordan
     15.3.8. Palestine
     15.3.9. Iraq
     15.3.10. KSA
     15.3.11. Iran
    15.4. Market Attractiveness Analysis By Country
    16. UAE Market Analysis 2017 to 2022 and Forecast 2023 to 2033
    16.1. Introduction
    16.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022
    16.3. Current and Future Market Size (US$ Million) Analysis By Market Taxonomy, 2023 to 2033
     16.3.1. By Drug
     16.3.2. By Drug Class
     16.3.3. By Dosage Form
     16.3.4. By Indication
     16.3.5. By Distribution Channel
    16.4. Drivers and Restraints - Impact Analysis
    16.5. Market Attractiveness Analysis By UAE
    17. Kuwait Market Analysis 2017 to 2022 and Forecast 2023 to 2033
    17.1. Introduction
    17.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022
    17.3. Current and Future Market Size (US$ Million) Analysis By Market Taxonomy, 2023 to 2033
     17.3.1. By Drug
     17.3.2. By Drug Class
     17.3.3. By Dosage Form
     17.3.4. By Indication
     17.3.5. By Distribution Channel
    17.4. Drivers and Restraints - Impact Analysis
    17.5. Market Attractiveness Analysis By Kuwait
    18. Qatar Market Analysis 2017 to 2022 and Forecast 2023 to 2033
    18.1. Introduction
    18.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022
    18.3. Current and Future Market Size (US$ Million) Analysis By Market Taxonomy, 2023 to 2033
     18.3.1. By Drug
     18.3.2. By Drug Class
     18.3.3. By Dosage Form
     18.3.4. By Indication
     18.3.5. By Distribution Channel
    18.4. Drivers and Restraints - Impact Analysis
    18.5. Market Attractiveness Analysis By Qatar
    19. Bahrain Market Analysis 2017 to 2022 and Forecast 2023 to 2033
    19.1. Introduction
    19.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022
    19.3. Current and Future Market Size (US$ Million) Analysis By Market Taxonomy, 2023 to 2033
     19.3.1. By Drug
     19.3.2. By Drug Class
     19.3.3. By Dosage Form
     19.3.4. By Indication
     19.3.5. By Distribution Channel
    19.4. Drivers and Restraints - Impact Analysis
    19.5. Market Attractiveness Analysis By Bahrain
    20. Oman Market Analysis 2017 to 2022 and Forecast 2023 to 2033
    20.1. Introduction
    20.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022
    20.3. Current and Future Market Size (US$ Million) Analysis By Market Taxonomy, 2023 to 2033
     20.3.1. By Drug
     20.3.2. By Drug Class
     20.3.3. By Dosage Form
     20.3.4. By Indication
     20.3.5. By Distribution Channel
    20.4. Drivers and Restraints - Impact Analysis
    20.5. Market Attractiveness Analysis By Oman
    21. Lebanon Market Analysis 2017 to 2022 Forecast 2023 to 2033
    21.1. Introduction
    21.2. Pricing Analysis
    21.3. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022
    21.4. Current and Future Market Size (US$ Million) Analysis By Market Taxonomy, 2023 to 2033
     21.4.1. By Drug
     21.4.2. By Drug Class
     21.4.3. By Dosage Form
     21.4.4. By Indication
     21.4.5. By Distribution Channel
    21.5. Drivers and Restraints - Impact Analysis
    21.6. Market Attractiveness Analysis By Lebanon
    22. Jordan Market Analysis 2017 to 2022 and Forecast 2023 to 2033
    22.1. Introduction
    22.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022
    22.3. Current and Future Market Size (US$ Million) Analysis By Market Taxonomy, 2023 to 2033
     22.3.1. By Drug
     22.3.2. By Drug Class
     22.3.3. By Dosage Form
     22.3.4. By Indication
     22.3.5. By Distribution Channel
    22.4. Drivers and Restraints - Impact Analysis
    22.5. Market Attractiveness Analysis By Jordan
    23. Palestine Market Analysis 2017 to 2022 and Forecast 2023 to 2033
    23.1. Introduction
    23.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022
    23.3. Current and Future Market Size (US$ Million) Analysis By Market Taxonomy, 2023 to 2033
     23.3.1. By Drug
     23.3.2. By Drug Class
     23.3.3. By Dosage Form
     23.3.4. By Indication
     23.3.5. By Distribution Channel
    23.4. Drivers and Restraints - Impact Analysis
    23.5. Market Attractiveness Analysis By Palestine
    24. Iraq Market Analysis 2017 to 2022 and Forecast 2023 to 2033
    24.1. Introduction
    24.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022
    24.3. Current and Future Market Size (US$ Million) Analysis By Market Taxonomy, 2023 to 2033
     24.3.1. By Drug
     24.3.2. By Drug Class
     24.3.3. By Dosage Form
     24.3.4. By Indication
     24.3.5. By Distribution Channel
    24.4. Drivers and Restraints - Impact Analysis
    24.5. Market Attractiveness Analysis By Iraq
    25. KSA Market Analysis 2017 to 2022 and Forecast 2023 to 2033
    25.1. Introduction
    25.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022
    25.3. Current and Future Market Size (US$ Million) Analysis By Market Taxonomy, 2023 to 2033
     25.3.1. By Drug
     25.3.2. By Drug Class
     25.3.3. By Dosage Form
     25.3.4. By Indication
     25.3.5. By Distribution Channel
    25.4. Drivers and Restraints - Impact Analysis
    25.5. Market Attractiveness Analysis By KSA
    26. Iran Market Analysis 2017 to 2022 and Forecast 2023 to 2033
    26.1. Introduction
    26.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022
    26.3. Current and Future Market Size (US$ Million) Analysis By Market Taxonomy, 2023 to 2033
     26.3.1. By Drug
     26.3.2. By Drug Class
     26.3.3. By Dosage Form
     26.3.4. By Indication
     26.3.5. By Distribution Channel
    26.4. Drivers and Restraints - Impact Analysis
    26.5. Market Attractiveness Analysis By Iran
    27. Market Structure Analysis
    27.1. Market Analysis by Tier of Companies
    27.2. Market Share Analysis of Top Players
    27.3. Market Presence Analysis
     27.3.1. Regional Footprint Analysis
     27.3.2. Product Footprint Analysis
     27.3.3. Channel Footprint Analysis
    28. Competition Analysis
    28.1. Competition Dashboard
    28.2. Competition Benchmarking
    28.3. Competition Deep Dive
     28.3.1. AbbVie Inc.
     28.3.1.1. Overview
     28.3.1.2. Product Portfolio
     28.3.1.3. Key Financials
     28.3.1.4. SWOT Analysis
     28.3.1.5. Sales Footprint
     28.3.1.6. Strategy Overview
     28.3.1.7. Key Developments
      28.3.1.7.1. Marketing Strategies
      28.3.1.7.2. Product Strategies
      28.3.1.7.3. Channel Strategies
     28.3.2. Eisai Co Ltd
     28.3.2.1. Overview
     28.3.2.2. Product Portfolio
     28.3.2.3. Key Financials
     28.3.2.4. SWOT Analysis
     28.3.2.5. Sales Footprint
     28.3.2.6. Strategy Overview
     28.3.2.7. Key Developments
      28.3.2.7.1. Marketing Strategies
      28.3.2.7.2. Product Strategies
      28.3.2.7.3. Channel Strategies
     28.3.3. Zydus Cadila
     28.3.3.1. Overview
     28.3.3.2. Product Portfolio
     28.3.3.3. Key Financials
     28.3.3.4. SWOT Analysis
     28.3.3.5. Sales Footprint
     28.3.3.6. Strategy Overview
     28.3.3.7. Key Developments
      28.3.3.7.1. Marketing Strategies
      28.3.3.7.2. Product Strategies
      28.3.3.7.3. Channel Strategies
     28.3.4. AMillioneal Pharmaceuticals, Inc.
     28.3.4.1. Overview
     28.3.4.2. Product Portfolio
     28.3.4.3. Key Financials
     28.3.4.4. SWOT Analysis
     28.3.4.5. Sales Footprint
     28.3.4.6. Strategy Overview
     28.3.4.7. Key Developments
      28.3.4.7.1. Marketing Strategies
      28.3.4.7.2. Product Strategies
      28.3.4.7.3. Channel Strategies
     28.3.5. Pfizer Inc.
     28.3.5.1. Overview
     28.3.5.2. Product Portfolio
     28.3.5.3. Key Financials
     28.3.5.4. SWOT Analysis
     28.3.5.5. Sales Footprint
     28.3.5.6. Strategy Overview
     28.3.5.7. Key Developments
      28.3.5.7.1. Marketing Strategies
      28.3.5.7.2. Product Strategies
      28.3.5.7.3. Channel Strategies
     28.3.6. Amgen Inc.
     28.3.6.1. Overview
     28.3.6.2. Product Portfolio
     28.3.6.3. Key Financials
     28.3.6.4. SWOT Analysis
     28.3.6.5. Sales Footprint
     28.3.6.6. Strategy Overview
     28.3.6.7. Key Developments
      28.3.6.7.1. Marketing Strategies
      28.3.6.7.2. Product Strategies
      28.3.6.7.3. Channel Strategies
     28.3.7. Celltrion, Inc.
     28.3.7.1. Overview
     28.3.7.2. Product Portfolio
     28.3.7.3. Key Financials
     28.3.7.4. SWOT Analysis
     28.3.7.5. Sales Footprint
     28.3.7.6. Strategy Overview
     28.3.7.7. Key Developments
      28.3.7.7.1. Marketing Strategies
      28.3.7.7.2. Product Strategies
      28.3.7.7.3. Channel Strategies
     28.3.8. Coherus BioSciences, Inc.
     28.3.8.1. Overview
     28.3.8.2. Product Portfolio
     28.3.8.3. Key Financials
     28.3.8.4. SWOT Analysis
     28.3.8.5. Sales Footprint
     28.3.8.6. Strategy Overview
     28.3.8.7. Key Developments
      28.3.8.7.1. Marketing Strategies
      28.3.8.7.2. Product Strategies
      28.3.8.7.3. Channel Strategies
     28.3.9. F. Hoffmann–La Roche Ltd
     28.3.9.1. Overview
     28.3.9.2. Product Portfolio
     28.3.9.3. Key Financials
     28.3.9.4. SWOT Analysis
     28.3.9.5. Sales Footprint
     28.3.9.6. Strategy Overview
     28.3.9.7. Key Developments
      28.3.9.7.1. Marketing Strategies
      28.3.9.7.2. Product Strategies
      28.3.9.7.3. Channel Strategies
     28.3.10. Alexion
     28.3.10.1. Overview
     28.3.10.2. Product Portfolio
     28.3.10.3. Key Financials
     28.3.10.4. SWOT Analysis
     28.3.10.5. Sales Footprint
     28.3.10.6. Strategy Overview
     28.3.10.7. Key Developments
      28.3.10.7.1. Marketing Strategies
      28.3.10.7.2. Product Strategies
      28.3.10.7.3. Channel Strategies
     28.3.11. Janssen Biotech, Inc.
     28.3.11.1. Overview
     28.3.11.2. Product Portfolio
     28.3.11.3. Key Financials
     28.3.11.4. SWOT Analysis
     28.3.11.5. Sales Footprint
     28.3.11.6. Strategy Overview
     28.3.11.7. Key Developments
      28.3.11.7.1. Marketing Strategies
      28.3.11.7.2. Product Strategies
      28.3.11.7.3. Channel Strategies
     28.3.12. Hikima Pharmaceuticals plc.
     28.3.12.1. Overview
     28.3.12.2. Product Portfolio
     28.3.12.3. Key Financials
     28.3.12.4. SWOT Analysis
     28.3.12.5. Sales Footprint
     28.3.12.6. Strategy Overview
     28.3.12.7. Key Developments
      28.3.12.7.1. Marketing Strategies
      28.3.12.7.2. Product Strategies
      28.3.12.7.3. Channel Strategies
    29. Assumptions and Acronyms Used
    30. Research Methodology

    Pricing

    Currency Rates
    How Do Licenses Work?

    How Do Licenses Work?

    The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

    • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

    • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

    • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

    • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

    • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

    License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

    Head shot

    Questions or Comments?

    Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
    Chat Now
    Contact Us